Aspire IRB, Independent Review Board is Breaking new Ground Overseeing Clinical Research Trials
News Sep 15, 2008
Aspire IRB announces record growth for the third consecutive year. Sales have tripled since their first year and consecutively grossed seven figures annually. 2008 is a very exciting year for Aspire IRB a women owned and certified independent review board overseeing clinical research trials making sure the research is well designed and risks are as minimal as possible protecting the rights of human participants.
“Our business is about people and that is what we focus on. As we enter our fifth year in business Aspire IRB has launched a new branding strategy and web site www.aspire-irb.com focusing on our commitment to excellence and integrity within the research field. We are dedicated to not being your ordinary IRB”, states Cathryn Taub, CEO, Aspire IRB.
Aspire IRB has become successful forging new paths in clinical research since it’s inception in 2004. They were the IRB of record for the first Microdosing or Phase 0 study. This gives biopharmaceutical sponsors the opportunity to obtain early human pharmacokinetic (PK) data on drug candidates more accurately and faster than traditional Phase I Studies.
Aspire IRB’s reputation and dedication to building relationships, being innovative and flexible in the research industry has been instrumental to their sales and growth. They have overseen over 1000 phase 0-IV clinical trials including: Diabetes, Cancer, Multiple Sclerosis ALS, Sleep Disorders, Stress, Depression, and Obesity.
To demonstrate it’s commitment to the protection of human research participants, Aspire IRB has applied for accreditation from The Association for the Accreditation of Human Research Protection Programs, Inc. (AAHRPP).
“They promote the highest quality research through an accreditation process that helps organizations worldwide strengthen their human research protection programs”. “We are dedicated to being the best independent review board and being certified helps us achieve that,” explains Cathryn.
Aspire IRB is setting new standards for the research industry and launched “A.S.A.P.” Aspire’s Simple Automated Portal allowing clients to securely access the web site 24 hours a day 7 days a week to view the latest information regarding their studies. A.S.A.P. offers clients an efficient way to retrieve approval documents any time.
“Our goals is to give our industry and clients the most effective technology and be responsive to our clients needs helping them provide research of the highest standards that is safe for participants,” explains Alycia Huston, COO, Aspire IRB.
“Aspire IRB is excited to announce that Dr. Currien MacDonald, MD has joined our team as Medical Director. He has been a very active member of our review board. His appointment to this invaluable position was the natural progression for the growth and commitment of Aspire IRB to the industry. His knowledge and passion for research and the health field is inspirational. Dr. MacDonald’s expertise in clinical trials and medicine have made him a highly respected resource for our clients, the local community and the media,” states, Cathryn.
Dr. MacDonald was recently featured on a local program about the benefits of participating in research and the rights of research participants. He was also interviewed on live television about the rising epidemic of stress, the impact it has on people’s health and how to relieve it.
Aspire has also expanded the Board and has announced the appointment of Pediatrician, Dr. Robert Bourdon Daigneault, M.D. currently Staff Physician for Boston Medical Group. This will increase ASPIRE’S diversity and ability to assist companies administering pediatric clinical trials.
Bicycle Therapeutics Expands Strategic Partnership with AstraZenecaNews
New programs added in respiratory and cardio-metabolic diseases.READ MORE
Worldwide Clinical Trials Receives 2018 CRO Leadership AwardsNews
Life Science Leader and Industry Standard Research assess 70 contract research organizations, honoring Worldwide Clinical Trials for fifth consecutive year.READ MORE
Tuberculosis: Pharmacists Develop Substance to Counteract Antimicrobial ResistanceNews
Antimicrobial resistance is on the rise worldwide. This is becoming a problem for infectious diseases like tuberculosis as there are only a few active substances available to combat such diseases. Pharmacists have now found a way to increase the efficacy of a common tuberculosis agent while, at the same time, reducing resistance to it.READ MORE
Comments | 0 ADD COMMENT
2nd Annual Artificial Intelligence in Drug Development Congress
Sep 20 - Sep 21, 2018